Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
- Conditions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Ulucanlar Eye Training and Research Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT03313401
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2023-04-13
- Target Recruit Count
- 170
- Registration Number
- NCT03279289
- Locations
- 🇪🇸
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, Spain
Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Barts & The London NHS Trust
- Registration Number
- NCT03264274
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Graybug Vision
- Target Recruit Count
- 32
- Registration Number
- NCT03249740
- Locations
- 🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States
🇺🇸Retina Research Center, PLLC, Austin, Texas, United States
🇺🇸Retinal Consultants of Arizona, Gilbert, Arizona, United States
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 132
- Registration Number
- NCT03186326
- Locations
- 🇫🇷
Ch - Centre Hospitalier Intercommunal, Villeneuve-Saint-Georges, France
🇫🇷Ch - Centre Hospitalier Du Pays D'Aix, Aix-en-Provence, France
🇫🇷Privé - Institut Sainte Catherine, Avignon CEDEX, France
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Amy C Schefler, MD
- Target Recruit Count
- 40
- Registration Number
- NCT03085784
- Locations
- 🇺🇸
Retina Consultants of Houston/Texas Medical Center, Houston, Texas, United States
🇺🇸Retina Consultants of Houston, Katy, Texas, United States
🇺🇸Retina Consultants of Houston/The Woodlands, The Woodlands, Texas, United States
Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Southeast Retina Center, Georgia
- Target Recruit Count
- 24
- Registration Number
- NCT02976012
- Locations
- 🇺🇸
Southeast Retina Center, PC, Augusta, Georgia, United States
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02878681
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Charles C Wykoff, PhD, MD
- Target Recruit Count
- 43
- Registration Number
- NCT02863354
- Locations
- 🇺🇸
Retina Consultants of Houston/The Medical Center, Houston, Texas, United States
🇺🇸Retina Consultants of Houston, The Woodlands, Texas, United States
🇺🇸Retina Consultants of Houston/Katy office, Katy, Texas, United States
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT02797704
- Locations
- 🇮🇱
Rabin Medical Center, Petah Tikva, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.